Crossmark

KRAS or BRAF mutations cause hepatic vascular cavernomas treatable with MAP2K–MAPK1 inhibition

Crossref DOI link: https://doi.org/10.1084/jem.20192205

Published Online: 2020-05-13

Published Print: 2020-07-06

Update policy: https://doi.org/10.1084/jem.crossmarkpolicy

Authors

Janardhan, Harish Palleti https://orcid.org/0000-0002-9923-9147
Meng, Xiuling

Dresser, Karen https://orcid.org/0000-0002-8599-4352
Hutchinson, Lloyd

Trivedi, Chinmay M. https://orcid.org/0000-0002-3544-0474
Funding

Funding for this research was provided by:

National Institutes of Health (HL141377)
License Information

Version of Record valid from 2020-05-13

Version of Record valid from 2021-01-03